![](https://news.europawire.eu/wp-content/uploads/2020/11/AstraZeneca’s-Imfinzi-durvalumab-approved-in-the-US-for-new-four-week-1500mg-fixed-dosing-option-144x144.png)
(PRESS RELEASE) CAMBRIDGE, 20-Nov-2020 — /EuropaWire/ — AstraZeneca (LON: AZN), a global, science-led biopharmaceutical company, has announced the US Food and Drug Administration (FDA) approval of its Imfinzi (durvalumab) for an additional dosing option, a 1,500mg fixed dose every four … Read the full press release